{
  "docId": "019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "docSlug": "4047dd7a7e0f28ca31128b58ef648c55",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 39,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The slide uses a three-column layout to categorize performance metrics and clinical milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b48b-74ad-8fcb-69ba4c0494fb/6",
  "deckHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "deckJsonHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb.json",
  "deckAnchorHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.84
      },
      "kind": "callout",
      "text": "Exceptional volume of Phase III read-outs highlights breadth of portfolio",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "817bd2f9-f110-4db3-90b3-712982888cea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for year-to-date (YTD) September 2021, unless stated otherwise. CVRM = Cardiovascular, Renal and Metabolism; COVID-19 = coronavirus disease 2019; n/m = growth rate not meaningful.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4a82b92-d192-4eb8-a183-cc690b7bb3ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "list",
      "text": "Robust growth: Total Revenue $25,406m (+28%), Core EPS $3.59 (+23%), 2021 Guidance updated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "166808ab-53e5-4878-a4bc-40da52190d23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.35,
        "y": 0.23
      },
      "kind": "list",
      "text": "Broad-based performance: Oncology $9,744m (+16%), BioPharmaceuticals, Rare Disease $1,311m, Other medicines $1,648m (-16%), Pandemic COVID-19 vaccine $2,219m",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "204166cd-59da-42f3-ba25-85f8b65470a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.67,
        "y": 0.23
      },
      "kind": "list",
      "text": "Following the science: Multiple positive Phase III results including Lynparza, Enhertu, Imfinzi, PT027, AZD7442, ALXN1840",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "864a1e44-d7e9-43de-bbf7-71a3fc9e921a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Positioned for long term sustainable growth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b476103-f2cd-4012-a856-5da4e6bbf778",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Year to date and Q3 2021: key highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fd7a3fd-11ae-44e5-84e0-7d5697a9908a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 1,
      "beatId": "7ec854af-cea1-4b2a-a408-59dac936096b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Attention",
      "beatSlug": "monroes-sequence-attention",
      "evidence": "The document starts with a clear and concise overview of the company's performance and key highlights.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "c7b1068b-597e-4504-a69d-21dd22f3fa84",
      "evidence": "The document presents a clear logic chain, connecting the company's performance to its strategic priorities.",
      "position": 0,
      "objective": "To present the company's financial results and pipeline, and demonstrate growth and innovation.",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}